Latest News
Vera Therapeutics, Inc.
- Is Phase III Kidney Disease Data Altering The Investment Case For Vera Therapeutics (VERA)?
- Cantor Fitzgerald reiterates Vera Therapeutics stock rating on kidney drug data
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...
- Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026
- Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026
- Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug
- Vera Therapeutics to Host ASN Kidney Week Investor Webcast
- Vera Therapeutics (NasdaqGM:VERA) Stock Forecast & Analyst Predictions
- Vera Therapeutics (VERA) Stock Dropped, So What Is Behind The Move?
- Vera Therapeutics Stock In Focus As Kidney Trial Results Head To ASN Conference
- Vera Therapeutics (VERA) Heads Into ASN Kidney Week As Its Undervalued Narrative Faces A Test
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Headlines from the last 30 days, linking to the original publishers. See all market news →